The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, Diabetic Retinopathy (DR) and Glaucoma
Overview
- Phase
- Early Phase 1
- Intervention
- Not specified
- Conditions
- Age-Related Macular Degeneration
- Sponsor
- MCPHS University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Revised Self Report Assessment of Functional Visual
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
The goal of this clinical trial is to learn if education about additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies will improve medication management skills. The main questions it aims to answer are:
Does additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies improve medication management skills, reduce errors and improve functional use of remaining vision for this task?
Participants will:
Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Clients with AMD, DR or Glaucoma who choose to receive the one hour OT service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills.
Detailed Description
Many clients with low vision are unaware of OT, or the services OT can provide to assist with low vision needs. Clients with AMD, DR or Glaucoma who choose to receive the one hour OT service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills. Clients will complete the MediCog and the Revised-Self-Report Assessment of Functional Visual Performance (R-SRAFVP) assessment tools with the assistance of the OT. These tools will inform the therapist to areas of client needs and allow for focus on intervention to support these challenges. Follow up in OT 4 weeks post intervention will allow therapist to reassess the effectiveness of interventions provided via a phone or in-person interview as well as provide the assessments again. Second set of data from these assessments will be compared to initial findings obtained.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clients with AMD, DR or Glaucoma
- •Clients who choose to participate will allow their deidentified data to be evaluated for outcomes.
Exclusion Criteria
- •Clients with other age related eye diseases other than AMD, DR or Glaucoma.
- •Clients who do not wish to participate in this study.
Outcomes
Primary Outcomes
Revised Self Report Assessment of Functional Visual
Time Frame: Results from the Revised-Self-Report Assessment of Functional Visual Performance assessment will be determined on day 1 and 4 weeks later
A standardized assessment which provides information on how well adults with vision loss can perform daily tasks. This tool has 33 assessment components and a higher score indicates less functional impairment. A lower score indicates a higher impairment.
MediCog Screening Tool
Time Frame: Results from the MediCog will be determined on day 1 and will be obtained 4 weeks later
The Medi-Cog has a maximum score of 10 points, and a score of 7 or lower may indicate cognitive impairment.